1. Home
  2. ACXP vs SYNX Comparison

ACXP vs SYNX Comparison

Compare ACXP & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.50

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$1.07

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACXP
SYNX
Founded
2017
2005
Country
United States
Israel
Employees
N/A
37
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
7.3M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
ACXP
SYNX
Price
$1.50
$1.07
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$95.50
N/A
AVG Volume (30 Days)
78.2K
25.4K
Earning Date
05-12-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$32.35
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.73
52 Week High
$8.34
$2.15

Technical Indicators

Market Signals
Indicator
ACXP
SYNX
Relative Strength Index (RSI) 43.91 44.81
Support Level $1.37 $1.04
Resistance Level $1.75 $1.25
Average True Range (ATR) 0.14 0.07
MACD 0.02 0.00
Stochastic Oscillator 39.02 34.44

Price Performance

Historical Comparison
ACXP
SYNX

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sells push-to-talk devices, communication controllers, and communication device cables and connectors. Geographically, it generates the majority of its revenue from Israel.

Share on Social Networks: